SHANGHAI, April 17, 2025 /PRNewswire/ -- In a significant gathering of industry minds, Henlius (2696.HK) hosted its annual Global R&D Day on April 17, 2025, themed "Collaborate to Create." This event drew an impressive assembly of senior executives, scientific experts, and industry leaders who came together to engage in discussions centered on research and development (R&D) advancements, strategic planning initiatives, and the latest breakthroughs in therapeutic treatments. The conference attracted hundreds of participants from various sectors, including academia, industry, and investment, signaling the importance of collaboration in the healthcare landscape.

During the event, Henlius proudly showcased its robust and innovative pipeline of products designed to address critical unmet medical needs, particularly in the realms of lung and gastrointestinal cancers. Among the highlighted therapies were serplulimab, a monoclonal antibody targeting PD-1, HLX22, an anti-HER2 monoclonal antibody, and HLX43, a PD-L1 antibody-drug conjugate (ADC). Notably, HLX43 stands out as Chinas first and the worlds second PD-L1 ADC, which integrates a proprietary antibody with MediLinks dual-release payload, demonstrating promising preclinical efficacy along with strong safety profiles.

HLX22, on the other hand, is specifically designed to treat HER2-positive gastric cancer. It employs a novel mechanism aimed at obstructing tumor signaling pathways, positioning it as a potential first-line therapy for patients suffering from HER2-positive gastric cancer, as well as serving as a treatment option for other HER2-positive malignancies.

In addition to its innovative pipeline, Henlius also illuminated its three groundbreaking technology platforms. Among these are the Hinova TCE platform, which focuses on tri-specific T-cell engagers for solid tumors, the proprietary ADC platform named Hanjugator, and the AI-driven drug discovery platform called HAI Club. These platforms have collectively formed a collaborative R&D matrix aimed at accelerating the development of differentiated therapies. Furthermore, Henlius is making strides in the development of its proprietary hyaluronidase, Henozye, and subcutaneous injection technologies, which are designed to speed up formulations for both novel drugs and biosimilars while also extending product lifecycles.

A key focal point for Henlius is globalization, with Japan being prioritized as a strategic market under its "Internationalization 2.0" strategy. The organization is keenly leveraging Japans aging population and favorable regulatory environment to expedite clinical trials for HLX22 and serplulimab (anti-PD-1). The company aims to create an end-to-end value chain that connects R&D with commercialization, ensuring efficient delivery of its innovative therapies to market. A highlight of the event was the "Partnering for Success" panel, featuring 2022 Nobel Laureate Prof. Carolyn Bertozzi, who emphasized the potential of sialoglycan-targeting therapies in both oncology and immunology. Through its collaboration with Henlius, the development of the human sialidase fusion protein HLX79 (E-602) has seen significant acceleration.

Industry leaders participating in the event underscored Henlius integrated capabilities in antibody development, clinical execution, and global-quality manufacturing as vital components in forming impactful alliances. Driven by trust-oriented partnerships, Henlius is actively working to expand its therapeutic ecosystem on a global scale.

The event concluded with a strong call for industry-wide collaboration aimed at bridging the gap between preclinical and clinical stages of drug development. Participants discussed leveraging AI and data-driven strategies to accelerate innovations centered around patient needs. With a vision for the future, Henlius aims to transform technological advancements into tangible clinical value by 2025, reinforcing China's burgeoning role in the global biopharmaceutical landscape.